A New Era of Cancer Treatment

We have one of the leading pipelines in cell therapy within the industry

Our pipeline currently includes investigational therapies and next generation technologies for a range of hematologic malignancies and solid tumors.

Chimeric Antigen Receptor (CAR)

Trial Indication/Area of Research Phase 1 Phase 2 Phase 3

axicabtagene ciloleucel

ZUMA-1

DLBCL, PMBCL & TFL

EU Regulatory Submission

ZUMA-5

Indolent NHL

ZUMA-6

DLBCL (PD-L1 mAb)

KTE-C19

ZUMA-2

MCL

ZUMA-3

Adult ALL

ZUMA-4

Pediatric ALL

KITE-585 (anti-BCMA)

MM

T Cell Receptor (TCR)

Trial Indication/Area of Research Phase 1 Phase 2 Phase 3

KITE-718 (MAGE A3/A6)

Solid Tumor

DLBCL = diffuse large b-cell lymphoma

PMBCL = primary mediastinal b-cell lymphoma

TFL = transformed follicular lymphoma

NHL = non-Hodgkin lymphoma

MM = multiple myeloma

MCL = mantle cell lymphoma

ALL = acute lymphoblastic leukemia

Note: ZUMA-7, ZUMA-8, Humanized anti-CD19 Control CAR (3rd Gen), KITE-796, and KITE-439 are at the pre-IND stage and are not displayed.

Kite Expanded Access Policy

Treating physicians may request information about Expanded Access for a Kite therapy by contacting Kite Medical Information at 1-844-454-KITE.

Kite will evaluate these requests individually. Kite may provide physician requested Expanded Access for a Kite therapy for patients with no other available therapies and for patients who are not eligible to participate in a current Kite clinical trial. Kite will acknowledge receipt of the request via telephone call or email within 5 business days of receipt of the request.

Information on all Kite trials can be found on ClinicalTrials.gov.

Pursuant to the 21st Century Cures Act: the posting of policies by manufacturers and distributors shall not serve as a guarantee of access to any specific investigational therapy by any individual patient.